Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma

2018 ◽  
Vol 79 (6) ◽  
pp. 643-649 ◽  
Author(s):  
Lisbeth A. Ambrosius ◽  
Deepika Dhawan ◽  
José A. Ramos-Vara ◽  
Audrey Ruple ◽  
Deborah W. Knapp ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
B Cell ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma

2020 ◽  
Vol 61 (14) ◽  
pp. 3395-3403
Author(s):  
San Krittikarux ◽  
Kitsada Wudhikarn ◽  
Nichthida Tangnuntachai ◽  
Thamathorn Assanasen ◽  
Narittee Sukswai ◽  
...  
Keyword(s):  
Cell Death ◽  
Tumor Microenvironment ◽  
Programmed Cell Death ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Survival Outcome ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma

2020 ◽  
Vol 14 (9) ◽  
pp. 1978-1997 ◽  
Author(s):  
Emil Aagaard Thomsen ◽  
Anne Bruun Rovsing ◽  
Mads Valdemar Anderson ◽  
Hanne Due ◽  
Jinrong Huang ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals PROGNOSTIC VALUE OF RED CELL DISTRIBUTION WIDTH AT DIAGNOSIS (RDW) IN DIFFUSE LARGE B‐CELL LYMPHOMA

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
J.M. Raya ◽  
P. López‐García ◽  
C. D. Reyes ◽  
M.J. Rodríguez‐Salazar ◽  
C. De Bonis ◽  
...  
Keyword(s):  
B Cell ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Red Cell Distribution Width ◽  
Red Cell ◽  
Cell Distribution ◽  
Distribution Width ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Ying Huang ◽  
Sheng Ye ◽  
Yabing Cao ◽  
Zhiming Li ◽  
Jiajia Huang ◽  
...  
Keyword(s):  
B Cell ◽  
Germinal Center ◽  
Survival Data ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Chinese Patients ◽  
First Line ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10, and MUM1 protein expression. The relationships between clinical characteristics, survival data, and immunophenotype (IHC) were studied. The 5-year overall survival (OS) in the CHOP and R-CHOP groups was 50.4% and 66.6% (P=0.031), respectively. GCB patients had a better 5-year OS than non-GCB patients whether treated with CHOP or not (65.0% versus 40.9%;P=0.011). In contrast, there is no difference in the 5-year OS for the GCB and non-GCB with R-CHOP (76.5% versus 61.3%;P=0.141). In non-GCB subtype, additional rituximab improved survival better than CHOP (61.3% versus 40.9%;P=0.0303). These results indicated that addition of rituximab to standard chemotherapy eliminates the prognostic value of IHC-defined GCB and non-GCB phenotypes in DLBCL by improving the prognostic value of non-GCB subtype of DLBCL.

Prognostic value of negative interim 2-[18F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma

2016 ◽  
Vol 71 (3) ◽  
pp. 280-286 ◽  
Author(s):  
S.H. Kwon ◽  
D.R. Kang ◽  
J. Kim ◽  
J.-K. Yoon ◽  
S.J. Lee ◽  
...  
Keyword(s):  
B Cell ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Pet Ct ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document